Class action lawsuits have been filed against drug manufacturers Sanofi-Aventis and Boehringer Ingelheim Pharmaceuticals. The lawsuits claim the companies knew or had reason to know that Zantac exposes users to harmful quantities of NDMA when ingested. Patients who have taken Zantac will be filing more lawsuits against the manufacturers. Those who may be eligible to file a Zantac lawsuit include people who regularly took Zantac OTC or prescription for at least 60 days and were diagnosed with a form of cancer.
The removal of Zantac and other ranitidine products from the market will encourage more patients and consumers to take legal action against ranitidine drug manufacturers.